A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman(King's College London), Nigel H. Russell(Nottingham University Hospitals NHS Trust), Charlotte S. Wilhelm-Benartzi(Cardiff University), Claire Arnold(University of Ulster), Claire Hemmaway(Auckland City Hospital), William Villiers(King's College London), Panagiotis Kottaridis(University College Hospital), Sophie Betteridge(Cardiff University), Amanda Gilkes(Cardiff University), Sylvie Freeman(University of Birmingham), Leona Batten(Institute of Cancer Research), Mike Dennis(The Christie NHS Foundation Trust), Emily L Hinson(Cardiff University), Michelle Kleeman(Guy's and St Thomas' NHS Foundation Trust), Priyanka Mehta, Joanna Canham(Cardiff University), Ulrik Malthe Overgaard(Copenhagen University Hospital), Nicola Potter(European Bioinformatics Institute), Julie Wych(Cardiff University), Richard Dillon(King's College London), Jamie Cavenagh(St Bartholomew's Hospital), Steven Knapper(Cardiff University)
Cited by 53
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750